Dr. Thomas M. Rinderknecht chairs Supervisory Board of GANYMED
GANYMED Pharmaceuticals AG announced the appointment of Dr. Thomas M. Rinderknecht as new Chairman of the Supervisory Board and the election of Dr. Alfred Scheidegger as new member of the Supervisory Board. Mr. Rinderknecht also invested an undisclosed amount in a second closing of GANYMED's Series B round in July 2006. He replaced Mr. Felix Hofstetter as Chairman of the Supervisory Board, who joined Migros Ostschweiz as Head of Finance, and Alfred Scheidegger replaced Dr. John Ryan, who joined Cambridge (Mass) based Aveo as Chief Medical Officer.
Dr. Thomas Rinderknecht, attorney at law, is a senior partner in the law firm RKS Rinderknecht Klein & Stadelhofer and has been specialized for many years in pharma and biotech law and matters. He has held functions on the board of directors of successful biotech companies such as Speedel Holding AG, Glycart Biotechnology AG and SkyePharma
Plc. Dr. Alfred Scheidegger is the founding partner and CEO of Nextech Venture, the lead investor in GANYMED. He also chairs the board of directors of The Genetics Company, Inc., Switzerland.
Other news from the department people
